Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons A10 and AS2-1 in Esophageal Adenocarcinoma
NCT00003487Phase 2Terminated
- Sponsor
- Burzynski Research Institute
- Start
- May 1996
- Primary completion
- Apr 2001
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of antineoplaston A10, antineoplaston AS2-1 in esophageal adenocarcinoma (EAC), sponsored by Burzynski Research Institute. Started May 1996; status: terminated.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT00003487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003487.